APA (7th ed.) Citation

J, K., Z, K., BG, K., M, O., R, N., P, H., . . . M, G. (2026). Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study. Pediatric blood & cancer, 73(7), e70318. https://doi.org/10.1002/1545-5017.70318

Chicago Style (17th ed.) Citation

J, Kovács, Köllő Z, Karvaly BG, Obeidat M, Nagy R, Hegyi P, Teutsch B, Tuboly E, and Garami M. "Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study." Pediatric Blood & Cancer 73, no. 7 (2026): e70318. https://doi.org/10.1002/1545-5017.70318.

MLA (9th ed.) Citation

J, Kovács, et al. "Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study." Pediatric Blood & Cancer, vol. 73, no. 7, 2026, p. e70318, https://doi.org/10.1002/1545-5017.70318.